Rydex Biotechnology Fund Class H
RYOAX
NASDAQ
| Weiss Ratings | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Reward Grade | C | |||
| Risk Index | Fair | |||
| Risk Grade | C | |||
| Company Info | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Provider | Rydex Funds | |||
| Manager/Tenure (Years) | Michael P. Byrum (28), Adrian Bachman (3), Brendan Cain (3), 2 others | |||
| Website | http://www.guggenheiminvestments.com | |||
| Fund Information | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Fund Name | Rydex Biotechnology Fund Class H | |||
| Category | Health | |||
| Sub-Category | Healthcare Sector Equity | |||
| Prospectus Objective | Specialty - Technology | |||
| Inception Date | Apr 01, 1998 | |||
| Open/Closed To New Investors | Open | |||
| Minimum Initial Investment | 2,500.00 | |||
| Minimum Subsequent Investment | -- | |||
| Front End Fee | -- | |||
| Back End Fee | -- | |||
| Dividends and Shares | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield | 0.00% | |||
| Dividend | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield (Forward) | 0.68% | |||
| Asset Allocation | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash | 0.19% | |||
| Stock | 99.93% | |||
| U.S. Stock | 94.65% | |||
| Non-U.S. Stock | 5.28% | |||
| Bond | 0.00% | |||
| U.S. Bond | 0.00% | |||
| Non-U.S. Bond | 0.00% | |||
| Preferred | 0.00% | |||
| Convertible | 0.00% | |||
| Other Net | -0.12% | |||
| Price History | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.72% | |||
| 30-Day Total Return | 3.78% | |||
| 60-Day Total Return | -1.81% | |||
| 90-Day Total Return | -0.81% | |||
| Year to Date Total Return | 2.60% | |||
| 1-Year Total Return | 39.62% | |||
| 2-Year Total Return | 42.57% | |||
| 3-Year Total Return | 39.96% | |||
| 5-Year Total Return | 19.93% | |||
| Price | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Closing Price | -- | |||
| 1-Month Low Price | -- | |||
| 1-Month High Price | -- | |||
| 52-Week Low Price | -- | |||
| 52-Week Low Price (Date) | -- | |||
| 52-Week High Price | -- | |||
| 52-Week High Price (Date) | -- | |||
| NAV | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Nav | $59.43 | |||
| 1-Month Low NAV | $55.69 | |||
| 1-Month High NAV | $61.73 | |||
| 52-Week Low NAV | $47.20 | |||
| 52-Week Low NAV (Date) | May 14, 2025 | |||
| 52-Week High NAV | $68.81 | |||
| 52-Week High Price (Date) | Nov 28, 2025 | |||
| Beta / Standard Deviation | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.79 | |||
| Standard Deviation | 16.27 | |||
| Balance Sheet | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Total Assets | 135.07M | |||
| Operating Ratios | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Expense Ratio | 1.64% | |||
| Turnover Ratio | 79.00% | |||
| Performance | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Last Bull Market Total Return | 37.60% | |||
| Last Bear Market Total Return | -10.29% | |||